DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20193544

The significance of expression of Her2neu in squamous cell carcinoma of uterine cervix

Shakti Kumar Yadav, Alekh Verma, Sompal Singh, Namrata Sarin

Abstract


Background: Cervical cancer is one of the leading causes of cancer related deaths among females. It arises from precursor lesions i.e. squamous intraepithelial lesions which are closely associated with infection by HPV. The ERBB2 protooncogene encodes for a cellular transmembrane protein (erb-b2) which has tyrosine kinase activity and has been implicated in the regulation of cellular growth and proliferation in various cancers. Application of monoclonal antibodies against Her2neu has shown higher response and improved survival. The aim of the study was to evaluate the expression of Her2neu in squamous cell carcinoma of cervix in relation to tumor characteristics and to compare the expression with normal control subjects.

Methods: It was a cross-sectional analytical study. Paraffin embedded tissue blocks from 30 cases of squamous cell carcinoma were obtained from the archives. Twenty age matched cases of normal cervix removed for lesions other than that related to cervix (like leiomyoma) were taken as control. Tumour characteristics were noted from the records. Her2neu immunostaining was done. Her2neu expression was scored as positive or negative according to the American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) scoring system for Her2neu. The Chi-square test was used to compare and find association between the variables. Student t-test was used to compare the variable between cases and controls.

Results: Her2neu was positive in 20% and negative in 80% cases of the study group. Her2neu positivity is not associated with size, histological grade and FIGO stage of the tumor. We found that all Her2neu positive cases showed no lymph node metastasis. This association between Her2neu positivity and lymph node status was statistically significant.

Conclusions: Her2neu immunoexpression is variable across various categories of squamous cell carcinoma. Her2neu positivity might be negatively associated with lymph node metastasis. However, a more comprehensive study encompassing various factors related to Her2neu overexpression is required to validate these results.


Keywords


Carcinoma, Cervix, ERBB2, Herceptin, Her2neu, Squamous

Full Text:

PDF

References


Denny L. Cervical cancer: prevention and treatment. Discov Med. 2012;14:125-31.

Wells M, Ostor AG, Franceschi S, et al. Epithelial tumors. In: Tavassoli FA, Devilee P, eds. Tumors of the breast and female genital organs. Lyons, France: IARC Press; 2003;262-79.

Long HJ, Bundy BN, Grendys EC, Jr., Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4626-33.

Califano D, Losito S, Pisano C, Santelli G, Greggi S, Iodice F, et al. Significance of erb-B2 immunoreactivity in cervical cancer. Front Biosci. 2006;11:2071-6.

Nevin J, Laing D, Kaye P, McCulloch T, Barnard R, Silcocks P, et al. The significance of Erb-b2 immunostaining in cervical cancer. Gynecol Oncol. 1999;73:354-8.

Shen L, Shui Y, Wang X, Sheng L, Yang Z, Xue D, et al. EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy. BMC Cancer. 2008;8:232.

Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Archives of Pathology and Laboratory Medicine. 2013;138:241-56.

Shanta V, Krishnamurthi S, Gajalakshmi CK, Swaminathan R, Ravichandran K. Epidemiology of cancer of the cervix: global and national perspective. J Indian Med Assoc. 2000;98:49-52.

Cirisano FD, Karlan BY. The role of the HER-2/neu oncogene in gynecologic cancers. J Soc Gynecol Investig. 1996;3:99-105.

Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990;50:4332-7.

Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol. 1999;26:51-9.

Rosty C, Couturier J, Vincent-Salomon A, Genin P, Freneaux P, Sigal-Zafrani B, et al. Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix. Int J Gynecol Pathol. 2004;23:13-7.

Chavez-Blanco A, Perez-Sanchez V, Gonzalez-Fierro A, Vela-Chavez T, Candelaria M, Cetina L, et al. HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer. 2004;4:59.

Gupta N, Singh S, Marwah N, Kumar S, Chabra S, Sen R. HER-2/neu expression in lesions of uterine cervix: is it reliable and consistent? Indian J Pathol Microbiol. 2009;52:482-5.